Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
July 7, 2023
- Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
July 7, 2023
- Japan Appropriately Reviewing Alzheimer’s Med Lecanemab: Minister
July 7, 2023
- Reflect Societal Values in Pricing of Regenerative Medicines: FIRM
July 7, 2023
- JPMA Pushes Simple Price Maintenance for Innovative Meds; PhRMA, EFPIA in Sync
July 6, 2023
- Discuss Drug Price Revision System That Doesn’t Cause Yakkasa: FPMAJ Chair
July 6, 2023
- Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
- Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
- Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
July 6, 2023
- 5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
July 6, 2023
- Hideo Hashimoto Named MOF Budget Examiner for Healthcare
July 5, 2023
- MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
- MHLW Panel OKs 282 More Health Damage Claims for COVID Vaccines
July 4, 2023
- Hiroyuki Uchiyama Tapped as Assistant Vice Minister for Pharma Promotion
July 3, 2023
- LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
- Average Annual Pay for PMDA Staffers at 7.71 Million Yen in FY2022
July 3, 2023
- MHLW Reports 3 New Cases of Inadvertent Use of Xocova in Pregnant Women
July 3, 2023
- Study Group of Lawmakers, Industry Urges Earlier Launch of Genome Analysis Project Organ
July 3, 2023
- MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
- Japan to Revise Generic Use Target to Value-Based Figure
June 30, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…